Business
IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022
CAESAREA, Israel, Nov. 28, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive
About this update from Icecure Medical Ltd.
[{"type":"text","content":"CAESAREA, Israel, Nov. 28, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the nine months ended September 30, 2022 on Monday, December 5, 2022 with a press release issued at 7:30 a.m. EST. IceCure's management team, joined by Dr. Hania Bednarski, oncoplastic breast surgeon and cryoablation specialist at Serenity Surgery & Wellness and author of \"Freeze Breast Cancer: your guide to an alternative breast cancer treatment\", will host a conference call that morning at 8:00 a.m. EST.\n \nDr. Bednarski uses the ProSense System to perform cryoablation procedures at her clinic, Serenity Surgery & Wellness, and she has conducted a webinar to train other surgeons on how to perform breast tumor cryoablation using IceCure's ProSense. Dr. Bednarski is a board certified general surgeon with a fellowship in aesthetic breast oncology, and she is known as an oncoplastic breast surgeon. Dr. Bednarski's goal is to reduce surgery's footprint. She is a comprehensive breast surgeon, performing all types of procedures, from minimally invasive breast biopsies, oncologic procedures, reconstruction of the breast, as well as cosmetic breast procedures.\nConference call:December 5, 2022 at 8:30 am ESTUS: 1-888-642-5032Israel/International: +972-3-9180609\nAbout IceCure Medical\nIceCure Medical (NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark.\nForward Looking Statements\nThis press release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal se...